继打出"创新药直营""剥离非优质资产聚焦主业""发布定增预案"等一整套促进创新药发展的组合拳之 后，罗欣药业本次收购少数股东股权，全资控股北京健康这一动作，背后蕴藏了哪些玄机？ 据悉，北京健康是罗欣药业旗下控股子公司，其核心业务是罗欣药业"替戈拉生片"(泰欣赞)的销售。据 悉，目前该产品已进院超过2500家，市场覆盖全国超过30个省份，米内网数据显示，在中国公立医疗机 构终端，泰欣赞实现快速成长，销售额已超6.3亿元，伴随该产品新适应症"与适当的抗生素联用以根除 幽门螺杆菌"纳入医保，2026年泰欣赞销量或将迎来爆发式增长，大幅拉动公司业绩上涨。 资产评估报告显示，北京健康2025年1月份至10月份净利润为8184.76万元，目前已实现盈利，基于其核 心产品泰欣赞良好的销售趋势，未来预期获利能够可靠估计，北京健康具备持续稳定的盈利能力，或将 呈井喷式增长。 与此同时，罗欣药业积极探索、拓展创新药多元化销售路径，已在全国布局院边关联药店合作，并率先 在浙江省开展连锁药店销售试点，2026年有望逐步推广至全国零售终端市场。尤为值得一提的是，其电 商业务线于2月9日传来好消息，泰欣赞作为中国首款自主研发的钾离子竞争 ...

公司已于2026年1月完成乐康制药100%股权转让(价格6250万元)，并于2025年12月完成罗欣安若维他 20%股权转让。这些处置有助于减少非经营性损益拖累，后续亏损影响将逐步消除。 经济观察网罗欣药业（002793）近期发布2025年业绩预告，预计归母净利润亏损显著收窄，同时核心创 新药替戈拉生片商业化放量，研发管线取得关键进展。 业绩经营情况 公司于2026年1月30日发布业绩预告，预计2025年归母净利润亏损收窄至-2.5亿元至-3.4亿元，较2024年 同期亏损(-9.65亿元)显著改善。扣非净利润预计为-2.6亿元至-3.5亿元。后续需关注审计机构的最终审计 结果，正式年报预计在2026年4月前披露。 业务进展情况 国家1类创新药替戈拉生片(泰欣赞)的三大适应症已全面纳入2025年版国家医保目录，支付端障碍消 除。2025年上半年，该产品进院数量激增近2500家，销售量同比增长约140%。未来其销售规模效应和 运营效率的提升值得跟踪。 产品研发进展 公司重点研发的注射用LX22001目前已进入Ⅱ期临床试验阶段；普卡那肽片Ⅲ期临床研究报告已完成定 稿，正推进地产化落地。这些创新药进展可能影响公司长 ...

2025年度公司整体仍未能实现盈利，主要因为上药罗欣业绩持续未达预期，公司确认了相关金融负债的 公允价值变动损失，该损失属于非经常性损益，最终金额将由公司聘请的审计机构进行审计后确定。公 司虽已启动对乐康制药、罗欣安若维他相关亏损业务的处置程序，但其在出售完成前的经营亏损仍对公 司本期业绩产生一定拖累。随着处置完毕，其亏损影响将减少。 近日，罗欣药业（002793）发布公告称，预计2025年度归母净利润约-3.4亿元至-2.5亿元，上年同期为 亏损9.65亿元。 公告指出，业绩变动的主要原因是公司继续战略性聚焦医药工业板块，特别是具有优势的消化系统领 域，在公司核心创新药产品替戈拉生片（商品名：泰欣赞 ）快速增长的拉动下，产品结构和增长质量 持续提升。 ...

本报讯(记者王僖)近日，罗欣药业（002793）集团股份有限公司(以下简称"罗欣药业")公告了其2025年 度业绩预告，预计该公司2025年度实现归属于上市公司股东的净利润为-3.4亿元至-2.5亿元，较2024年 度的-9.65亿元大幅收窄；扣除非经常性损益后的净利润预计为-3.5亿元至-2.6亿元，相比上年同期 的-7.68亿元也有显著改善。 财务数据显示，由于核心产品销量增长及费用控制优化，罗欣药业2025年前三季度毛利率提升至 51.8%，经营性现金流净额由负转正达到2.8亿元，表明公司盈利能力显著增强。截至2025年上半年，罗 欣药业拥有超过350项发明专利，并获得了多个国际市场的注册批件，彰显了其在全球市场的竞争力。 值得一提的是，在管线布局上，罗欣药业已形成"创新药引领、差异化仿制药支撑"的良性梯队。创新药 方面，除替戈拉生片新增适应症研发外，注射用LX22001等后续品种也在有序推进；仿制药方面，已基 本完成现有在售产品的一致性评价，并通过原料药与制剂一体化持续降本增效。 市场分析认为，2025年罗欣药业的经营状况显著好转，得益于"业绩底部反转+战略聚焦红利"的双重效 应。尽管该公司遭遇了非持 ...

Core Viewpoint - Recent asset transactions by Luoxin Pharmaceutical highlight the company's ongoing financial struggles, with significant losses and high debt levels prompting asset sales at steep discounts [1][2][6] Financial Performance - As of September 30, 2025, Luoxin Pharmaceutical's total assets were 12.00 billion, with total liabilities at 4.68 billion, resulting in a debt ratio of 61.65% [2][8] - The company reported a net loss of 1.44 billion for the first three quarters of 2025, following a loss of 14.48 billion in 2022 and 6.39 billion in 2023, totaling over 28 billion in losses over three years [10][11] - The company's cash reserves have drastically decreased from 20.02 billion at the end of 2021 to 3.93 billion by mid-2025, a decline of over 80% [11] Asset Sales - Luoxin Pharmaceutical sold its subsidiary, Lekang Pharmaceutical, for 62.5 million, significantly below its net asset value of 73.24 million and only 15% of its registered capital of 420 million [1][6] - The initial listing price for Lekang was 190 million, but after multiple price reductions, it was sold at a 67% discount [8] Business Challenges - The company's core generic drug business has been severely impacted by policy changes, with revenue from generics accounting for approximately 98% of total income, while the average gross margin in the industry has dropped from 75% in 2020 to about 60% [11] - Luoxin's revenue has plummeted from a peak of 6.48 billion in 2021 to 2.65 billion in 2024, indicating a significant contraction in business scale [10] Innovation and R&D - Despite the financial difficulties, Luoxin's innovative drug, Tegoprazan, has shown promising sales, exceeding 2.7 billion in the first half of 2025, marking a nearly 140% increase [12] - However, the company has reduced its R&D spending from 2.05 billion in 2022 to 0.63 billion in the first three quarters of 2025, indicating a shift towards marketing over research [12][13] - Luoxin plans to raise up to 842.4 million through a private placement to support R&D and working capital, but this funding will take time to materialize [12]

Group 1: Company Performance and Strategy - The company has strategically focused on the pharmaceutical industry, particularly in the digestive system sector, leading to continuous improvement in product structure and growth quality since 2025 [2]. - The core innovative drug, Tai Xin Zan (替戈拉生片), has seen significant growth, with nearly 2,500 medical institutions adopting it and a sales increase of approximately 140% year-on-year in the first half of 2025 [2][3]. - The gross profit margin for the first three quarters was 51.8%, an increase of 9.0 percentage points, and cash flow turned positive with an increase of 280 million [3]. Group 2: Product Development and Market Position - Tai Xin Zan has achieved full coverage in the medical insurance directory for its three approved indications, which is expected to further stimulate the acid suppression treatment market [5]. - Compared to PPIs, P-CABs like Tai Xin Zan have advantages such as rapid onset, prolonged acid suppression, and less dependency on food intake and genetic factors [4][6]. - The company is advancing its pipeline with the injection of LX22001 entering Phase II clinical trials and the completion of the Phase III clinical research report for Pucanate tablets [6]. Group 3: Financial and Operational Insights - The company plans to raise up to 842.4 million CNY through a specific issuance of A-shares, with the funds allocated for innovative drug research and development, raw material drug expansion, and working capital [9][10]. - The company has implemented a differentiated strategy for its generic drug products, focusing on maintaining supply and quality while controlling costs amid structural adjustments in the industry [8]. - The decrease in expense ratios is attributed to the scale effect from increased sales revenue and enhanced management practices, leading to optimized personnel allocation and budget control [12].

Group 1: Manufacturing Champions Recognition - Shandong Province's Industrial and Information Technology Department has announced the ninth batch of proposed manufacturing champions, with two companies from Linyi's Luozhuang District, including Luoxin Pharmaceutical and Lixin Aluminum, successfully recognized [1] - Luozhuang District has now cultivated a total of 1 national-level and 10 provincial-level manufacturing champions, creating a "1+10" champion enterprise matrix to enhance the region's manufacturing capabilities [1] Group 2: Luoxin Pharmaceutical Innovations - Luoxin Pharmaceutical, a top 100 pharmaceutical company in China, specializes in digestive system diseases and has developed the first domestically produced potassium ion competitive acid blocker, Tegoprazan (brand name: Taixinzan), which has received approval for three indications [4] - The drug is notable for its rapid onset of action within 30 minutes, long-lasting acid suppression, and convenience of use, with all three indications included in the national medical insurance catalog by 2025 [4] - Luoxin has been recognized multiple times for its contributions to the pharmaceutical industry, including national and provincial awards, and has established a comprehensive innovation capability across drug research, production, trade, and healthcare services [4] Group 3: Lixin Aluminum's Green Initiatives - Lixin Aluminum is recognized for its "short-process green industrial chain," achieving over 90% secondary utilization of aluminum resources through its recycling and processing model [8] - The company has an annual production capacity of 100,000 tons, which will increase to 300,000 tons per year after the completion of a new green recycled aluminum alloy project in 2024, with expected annual sales revenue of 2.5 billion yuan [8] - Lixin holds 14 national invention patents and 42 utility model patents, and has established multiple research and development platforms in collaboration with universities, achieving some technologies at an internationally advanced level [8] Group 4: Policy Support and Development Strategies - The Luozhuang District's Industrial and Information Technology Bureau aims to strengthen the cultivation mechanism for manufacturing champions through targeted policy guidance and financial support [9] - The district encourages companies to overcome critical technological challenges and promotes the transformation of scientific achievements [9] - The focus is on building a collaborative industrial community that integrates leading enterprises with small and medium-sized suppliers, leveraging the innovations of Luoxin and Lixin to elevate the entire industrial chain [9]